Physician profile
Stanislav V Byshenko
NPI 1891088415
$7,037.42
in general payments reported to CMS, 2019-2025
26 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $620 · 2021: $1,612 · 2022: $1,289 · 2023: $1,028 · 2024: $1,082 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,200.08 | 2019-2025 | Breztri, Farxiga |
| Amgen INC. | $905.99 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $797.38 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $767.10 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $686.99 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $500.48 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $377.97 | 2023-2025 | |
| Esperion Therapeutics, INC. | $262.16 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $206.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $192.45 | 2021 | |
| Abbvie INC. | $179.98 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $167.35 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $152.56 | 2020-2022 | |
| Boston Scientific Corporation | $143.17 | 2022 | |
| Genentech USA, INC. | $100.00 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.14 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $70.94 | 2019 | |
| Lundbeck LLC | $45.84 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $42.47 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.82 | 2019-2020 | |
| Exact Sciences Corporation | $36.98 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $16.05 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $15.77 | 2025 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $14.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.43 | 2021 | |
| Eisai INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislav Byshenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.